United States: Product Liability Update: January 2016

Last Updated: February 7 2016
Article by David R. Geiger and Catherine C. Deneke

Foley Hoag LLP publishes this quarterly Update concerning developments in product liability and related law of interest to product manufacturers and sellers.

Supreme Court Holds Defendant Cannot Moot Putative Class Action by Making Unaccepted Offer of Judgment for Complete Relief to Representative Plaintiff

In Campbell-Ewald Co. v. Gomez, No. 14-857, 2016 U.S. LEXIS 846 (S. Ct. Jan. 20, 2016), plaintiff filed a putative nationwide class action in the United States District Court for the Central District of California alleging the defendant multimedia developer violated the Telephone Consumer Protection Act ("TCPA") by sending unsolicited text messages to him and the other class members.  Before plaintiff moved for class certification, defendant filed an offer of judgment pursuant to Fed. R. Civ. P. 68 to allow judgment to be entered against defendant on plaintiff's individual claim in the amount of triple the statutory damages, as is available under the TCPA where a "defendant willfully or knowingly violate[s]" the statute.  The offer also included reimbursing plaintiff's costs, but not his attorneys' fees, and a stipulated injunction in which defendant denied liability but would henceforth be barred from sending any text messages that violated the TCPA.  Plaintiff did not accept defendant's offer within the 14-day window provided by Rule 68.  Thereafter, defendant moved to dismiss, arguing its offer of judgment mooted plaintiff's individual claims because it provided him complete relief and, because it was made before he had moved for class certification, the putative class claims were also moot.  The district court denied the motion to dismiss but awarded defendant summary judgment on other grounds.  On appeal, the United States Court of Appeals for the Ninth Circuit agreed the claims were not moot and also reversed the summary judgment decision, reinstating the action in its entirety.

Despite the non-final nature of the judgment below, the United States Supreme Court granted review to resolve a split among the federal circuits on the mootness issue—which was of considerable importance to class action litigation—and held plaintiff's claims were not moot.  The Court began by noting that "[a]n unaccepted settlement offer—like an unaccepted contract offer—is a legal nullity, with no operative effect," and that under the terms of Rule 68 itself an "unaccepted offer is considered withdrawn."  Accordingly, defendant's offer in this case, once rejected, had no continuing efficacy, the parties remained adverse and there was still a live case or controversy supporting federal court jurisdiction.  In this respect, therefore, the case differed from a series of tax collection cases that the Court had held moot after the railroads paid the taxes claimed, as in those cases the plaintiffs had actually been paid.  Further, while the putative class here lacked independent status because it was not yet certified, because plaintiff himself had a live claim he was entitled to the opportunity to argue for certification.

Finally, the Court acknowledged the dissent's argument that a no-mootness ruling would give too much power to individual plaintiffs to pursue a broad class action even though they had been offered complete relief for any unlawful conduct as to them.  But the Court countered that a contrary rule would give too much power to defendants who were guilty of unlawful conduct to avoid a potentially adverse class-wide decision solely by mooting the individual plaintiff's claim.

First Circuit Affirms Class Action Settlement Despite Disparity Between Refund Estimate in Class Notice and Actual Refund, Proof-of- Purchase Requirement for Objectors But Not Certain Claimants and Attorneys' Fee Award Following Defendant's Agreement Not to Oppose

In Bezdek v. Vibram USA, Inc., No. 15-1207, 2015 U.S. App. LEXIS 22925 (1st Cir. Dec 31, 2015), plaintiff purchasers of "barefoot" running footwear brought a putative class action against the manufacturer in the United States District Court for the District of Massachusetts alleging false and deceptive marketing about the product's health benefits. A later-filed but similar putative class action from another federal court was transferred to Massachusetts and consolidated with the first case.  After extensive written discovery but before plaintiffs moved for class certification, the parties submitted a proposed settlement agreement to the court for approval.

Under the terms of the settlement, defendant would create a $3.75 million fund from which refunds would be paid on a pro rata basis, the parties agreed it was reasonable to expect class members might receive refunds of $20 to $50 per pair, costs and attorneys' fees—which defendant agreed not to oppose if not exceeding 25% of the settlement fund—would be paid out of the fund and an injunction would order defendant to refrain from making representations about the product's health benefits unless supported by "competent and reliable scientific evidence."  In addition, individuals could participate in the settlement for no more than two pairs without written proof of purchase; for a larger claim, or to object to the settlement, such proof was required.  The district court preliminarily approved the settlement, certified a class for settlement purposes only and ordered notice sent to the class summarizing the settlement's terms.  Although written objections to the settlement were filed, after a fairness hearing the district court approved the settlement as "fair, reasonable, and adequate" under Fed. R. Civ. P. 23(e)(2).

On appeal to the United States Court of Appeals for the First Circuit, the objectors argued that (i) the class notice was misleading because it posited a recovery of $20 to $50, whereas the actual per-pair refund was only $8.44, and the discrepancy could have affected whether or not class members objected, (ii) it was punitive to require only objectors to provide proofs of purchase, (iii) the injunctive relief was inadequate, and (iv) the attorneys' fees awarded were unreasonable due to defendant's agreement not to oppose them up to 25% of the recovery.

On the first argument, the appellate court found no misrepresentation in the notice, as the numbers provided were only an estimate and the notice specifically warned the actual refund could decrease depending on the number of valid claims.  Moreover, despite the variance from initial estimates, the $8.44 actually awarded was a fair settlement because of the uncertainty of success at trial and the trial costs, which would decrease the net amount of any damages award.  The court also rejected the objectors' argument that class counsel should have anticipated the higher number of claims or waived some of their own fees to compensate class members, as objectors cited no legal authority and simply imagining a better settlement would not mean such a settlement was reasonable or feasible.

As for the objector standard, the court held that while the imposition of a proof-of-purchase standard for objectors but not for at least some class members was a factor that could bear on fairness, that disparity alone was not enough to render an otherwise fair settlement unfair.

Regarding the challenged injunctive relief, the objectors argued it only required the manufacturer to do what it was already legally obligated to do.  But the circuit court affirmed the district court's ruling that the requirement of competent and reliable scientific evidence to substantiate any health claims was a "valuable contribution," because allegedly false advertising formed the crux of the litigation.

Finally, on the attorneys' fees issue, the court cited its prior precedent that a "clear-sailing" agreement (i.e., an agreement not to challenge a fee application) was not per se unreasonable.

While fee awards following such agreements must be afforded extra scrutiny, the award here survived both because it was reasonable when compared to the "lodestar" amount—counsel's hours worked multiplied by reasonable hourly rates—and because other courts had found fees of 25% of a recovery to be reasonable.

Massachusetts Federal Court Finds Hospital Implanting Surgical Device Not Fraudulently Joined to Defeat Diversity Jurisdiction Where (1) It Was Plausible Massachusetts Would Recognize Breach of Warranty Claim Against Hospital, (2) Preemption and Statute of Limitations Defenses Were Not Unique to Hospital, (3) Plaintiff's Claims Were Not Preempted Because "Parallel" To Federal Law and (4) Claims Were Timely Under "Discovery Rule"

In Rosbeck v. Corin Group, PLC, No. 15-12954, 2015 U.S. Dist. LEXIS 145621 (D. Mass. Oct. 27, 2015), plaintiff sued three manufacturers of an implanted hip resurfacing system and the hospital where the implantation surgery occurred in Massachusetts Superior Court alleging he suffered injuries caused by the release of chromium and cobalt from abrasion of the implant.  Plaintiff brought claims against the manufacturers for negligence, breach of the implied warranty of merchantability (the Massachusetts near-equivalent of strict liability) and violation of Mass. Gen. L. ch. 93A (the Massachusetts unfair and deceptive practices statute), and alleged the implant's excessive wear and tear violated United States Food and Drug Administration regulations under the Federal Food, Drug and Cosmetic Act ("FDCA") and the manufacturers unrealistically lubricated the implant during simulator testing so it would appear to comply with the regulations.  Plaintiff also asserted a claim for breach of the implied warranty of merchantability against the hospital for its sale of the allegedly defective product.

After defendants removed the case to the United States District Court for the District of Massachusetts, plaintiffs sought remand to state court, arguing the federal court lacked diversity jurisdiction because they and the defendant hospital were all Massachusetts citizens.  One of the manufacturers opposed the motion to remand, arguing the hospital was fraudulently joined solely to defeat diversity because (1) Massachusetts has never recognized a breach of warranty claim for a medical product provided by a hospital, limiting its liability instead to medical malpractice, and any claim against the hospital was (2) preempted by the FDCA and (3) barred by the statute of limitations.

The court first noted that joinder of a defendant is fraudulent "where there is no reasonable possibility that the state's highest court would find that the complaint states a cause of action upon which relief may be granted against the non-diverse defendant."  In accord with other jurisdictions, the court should apply a standard of review "more lenient than that for a motion to dismiss" and resolve any ambiguities in favor of plaintiff.

On the breach of warranty issue, while the Massachusetts Supreme Judicial Court ("SJC") had not ruled on it and the majority of states rejected hospital warranty liability in favor of malpractice, at least one other state supreme court had permitted such a claim and the SJC could plausibly follow this minority view.  Defendants argued Massachusetts would follow the majority view because it had "demonstrated a public policy protective of hospitals" by creating medical malpractice tribunals to filter out frivolous claims and refusing to apply abnormally dangerous activity liability to hospitals, but the court was not persuaded that either fact meant the SJC would necessarily reject hospital warranty claims.  In addition, Massachusetts' Uniform Commercial Code warranty provisions expressly covered transactions involving the provision of both a good and services, as here, even though the ultimate success of plaintiff's claim might depend in part on what facts discovery revealed about the hospital's role.  Also, two other federal district courts had remanded similar cases where there was no appellate authority in those states regarding whether warranty claims could be asserted against hospitals.

The court also rejected defendant's arguments that joinder was fraudulent because plaintiff's claims were preempted or barred by the statute of limitations.  First, the court recognized the "common defense rule," adopted in other jurisdictions and based on United States Supreme Court precedent, under which there is no fraudulent joinder if "[plaintiff's] claim against the non-diverse defendants is no weaker than his claim against the diverse defendants," i.e., if defendant's argument applies to the case as a whole rather than just the allegedly fraudulently joined defendants.  Here, the preemption and statute of limitations arguments overlapped among the defendants as all were based on essentially the same set of factual allegations relating to non- compliance with the FDCA.

In addition, the court rejected the preemption and statute of limitations defenses on the merits.  The FDCA preempts only state law claims based on requirements that are "different from, or in addition to," the requirements of federal law.  Here plaintiff's state law claims stemmed "solely" from violations of the federal requirements, i.e., the FDCA-based wear and tear regulations.  Accordingly, plaintiff pled a claim that was "parallel" to and hence not preempted by federal law.

Regarding the three-year Massachusetts statute of limitations, under the "discovery rule" plaintiff's claim only accrued when he reasonably should have known he was harmed by defendant's conduct.  Here, while plaintiff was informed his blood contained sharply elevated levels of chromium and cobalt in August 2011 and did not sue until April 2015, no reasonable person should have known at the earlier time that the implant system was the cause of the blood results.  For all these reasons, the court granted plaintiffs' motion to remand.

Massachusetts Federal Court Applies Massachusetts Statute of Limitations to Claim Based on Product Use and Injury in Oklahoma, Where Plaintiff Saw Product Advertisement, Bought Product By Phone and Received Worker's Compensation Benefits in Massachusetts

In Elliston v. Wing Enters., No. 15-11739, 2015 U.S. Dist. LEXIS 155256 (D. Mass. Nov. 17, 2015), plaintiff sued a ladder manufacturer incorporated in Utah in the United States District Court for the District of Massachusetts after he was injured when the ladder's leg buckled during use.  Plaintiff saw advertisements for the ladder in Massachusetts, purchased the ladder by phone there and the ladder was delivered to his home there, but plaintiff never used the ladder until he brought it to his second home in Oklahoma, where the accident occurred. Defendant moved to dismiss, arguing Oklahoma's two-year statute of limitations applied and barred the claim, even though it was timely under Massachusetts's three-year statute. 

The Court began by citing the Restatement (Second) of Conflict of Laws, § 142, which states that a forum will apply its own statute of limitations unless the claim would be barred under the limitations law of a state with a more significant relationship to the parties and occurrence.  Defendant argued Oklahoma had a more significant interest in the action because it had a more significant relationship with the parties, product and occurrence than Massachusetts, but the court disagreed, finding Massachusetts had at least three substantial interests warranting application of its statute.  First, the state had an interest in providing a remedy for Massachusetts residents who were injured and holding manufacturers of defective products responsible; while plaintiff had a secondary home in Oklahoma, that did not diminish his Massachusetts residency. Second, Massachusetts had an interest based on the defendant's advertising and sales in the state.  Third, plaintiff held a Massachusetts construction supervisor's license, was a registered Massachusetts home improvement contractor and had received Massachusetts worker's compensation benefits due to his fall.  While the fact that the product was used and plaintiff's injury occurred in Oklahoma was relevant, that was only one aspect of plaintiff's claim—among other things, the product had been neither designed, manufactured nor sold in Oklahoma.  Accordingly, Oklahoma had only a minimal interest in the application of its statute of limitations, even though the analysis might be different if a more substantive law—such as one that sought to change the actual behavior of tortfeasors— were at stake.

Massachusetts Superior Court Applies Law of Colorado As Place of Injury in Claim Against Massachusetts Drug Manufacturer, As Massachusetts Did Not Have More Significant Relationship With Claim; Among Other Things, State's Product Liability Policy Focused on Deterrence and Compensation Was Not Superior to Colorado's Policy Balancing Those Concerns With Insurance Cost and Availability Concerns, Resulting in Cap on Non-Economic Damages Awards

In Ogburn-Sisneros v. Fresenius Med. Care Holdings, Inc., No. 131756, 2015 Mass. Super. LEXIS 96 (Super. Ct. Oct. 19, 2015), plaintiff sued several related companies responsible for the manufacture and sale of a kidney dialysis drug, alleging her decedent died as a result of defendants' failure to warn of the drug's risks.  At issue was whether Massachusetts or Colorado law applied to the claims.  Defendants were Massachusetts corporations and made all drug warning decisions in Massachusetts, but manufactured the drug in Ohio and Texas and distributed it throughout the United States.  Decedent resided, was prescribed and received dialysis treatment, including the drug, in Colorado, and also died there.

The court began by noting that Massachusetts follows the Restatement (Second) of Conflict of Laws ("Restatement") for its choice-of-law rules.  Under Restatement § 146, because plaintiff's claims were for personal injury, the law of Colorado—the state where the injury had occurred—should apply, unless some other state had a more significant relationship to the injury and parties. Restatement § 6(2) then lists six factors generally to be considered in determining which state has a more significant relationship to the injury and parties, and §145(2) lists three factors to be considered when applying § 6's principles in tort cases.

Turning to §6's general factors, the court first concluded that applying Colorado law was consistent with the interstate system's needs, because Colorado had substantial contacts with both the injury and parties.  With respect to the product liability policies of the two states, while Massachusetts focused broadly on deterring the sale of defective products and compensating injured individuals, Colorado balanced a concern about these issues with concerns about dramatic increases in the cost of, and difficulty in obtaining, insurance, as a result of which it imposed a $250,000 cap on non-economic damages awards ($500,000 if a court found justification by clear and convincing evidence); accordingly, Massachusetts' policy was not superior to Colorado's.  The §6 factors of certainty, predictability and uniformity were less important in tort cases than in contractual disputes where the parties give advance thought to the applicable law, and while it would be easier for a Massachusetts court to apply its own law, this factor could not outweigh all the other factors that weighed in favor of Colorado law.

The court then applied §145(2) and held Colorado had a more significant relationship to the injury and parties because the injury occurred there and the parties' relationship was centered there, as that was where decedent had been prescribed and received the drug.  The conduct causing decedent's injury also occurred in Colorado, because under prior precedent the relevant conduct in a prescription drug product liability case is the use of the product and any accompanying warnings, which occurred in Colorado, not the decisions regarding warnings, which occurred in Massachusetts.  For all these reasons, therefore, Colorado law applied.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Events from this Firm
12 Oct 2018, Other, Boston, United States

The New England Electricity Restructuring Roundtable has been meeting bimonthly since 1995 to discuss current topics related to important changes in the electric power industry in Massachusetts and throughout New England.

Similar Articles
Relevancy Powered by MondaqAI
Foley Hoag LLP
Foley Hoag LLP
Foley Hoag LLP
Foley Hoag LLP
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Foley Hoag LLP
Foley Hoag LLP
Foley Hoag LLP
Foley Hoag LLP
Related Articles
 
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions